Moderated by Hilary Rosselot, featuring Elizabeth Berry-Kravis, MD, PhD, Craig A. Erickson, MD, Randi J. Hagerman, MD, Reymundo Lozano, MD, MS, and Nicole Tartaglia, MD

Runtime: 1:20:29

Additional resources and controls for this video are accessible just below the video: Play/pause, volume, subtitles, view transcript, watch as picture-in-picture, or in fullscreen mode.

About the Speakers

Elizabeth Berry-Kravis, MD, PhD

Rush University Medical Center, Chicago
Professor, Pediatrics, Neurological Sciences, and Biochemistry

Elizabeth Berry-Kravis established the Fragile X Clinic and Research Program at Rush University Medical Center in 1992. She studies Fragile X syndrome medical issues, epilepsy, and psychopharmacology and provides care to over 700 patients with FXS. She has been a leader in translational research, including the development of outcome measures and biomarkers, natural history studies, newborn screening, and particularly clinical trials of new targeted treatments.

Dr. Berry-Kravis’s laboratory studies the cellular roles of the Fragile X protein (FMRP), its relationship to phenotypes, and the optimization of genetic testing methods. She is a longstanding member of the NFXF Scientific and Clinical Advisory Committee, and Clinical Trials Committee, and is the principal investigator of the CDC-funded FORWARD-MARCH natural history project for Fragile X.

Dr. Berry-Kravis attended the University of Notre Dame for her undergraduate studies and the University of Chicago for her doctoral degrees (MD and PhD) and training in pediatric neurology.

Craig A. Erickson, MD

Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine
Professor of Psychiatry

Dr. Craig Erickson is a Professor of Psychiatry at Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine-Affiliated. Dr. Erickson leads a neurodevelopmental clinical and research group focused on improving clinical care through research discovery. He is the director of the Cincinnati Fragile X Research and Treatment Center, one of the largest such programs in the world. He serves as the chair of the Clinical Trials Committee organized by the National Fragile X Foundation and is a leader in translational medicine efforts in Fragile X syndrome, autism, and related disorders. Additionally, he is the director of research in the Division of Psychiatry at Cincinnati Children’s Hospital.

Randi J. Hagerman, MD

University of California, Davis, MIND Institute, California
Medical Director (Fragile X Clinic), Distinguished Professor in the Department of Pediatrics, Endowed Chair in Fragile X Research

Developmental pediatrician Dr. Randi Hagerman co-founded the National Fragile X Foundation in 1984 and has helped guide the foundation ever since. In 2009, after more than 100 board meetings, Randi agreed that it was time to step aside and let others bring their expertise to the board.

There is no aspect of the NFXF that Randi has not helped shape. Her strength as both a clinician and researcher has informed the NFXF mission and strategic plan. She and her husband, Dr. Paul Hagerman, generously support the NFXF mission. While Randi is no longer a board member, she is active on the NFXF Scientific & Clinical Advisory Committee and the Fragile X Clinical & Research Consortium where she represents the UC Davis Medical Center’s MIND Institute as medical director of the Fragile X Clinic.

Randi continues to be a sought-after speaker and her work has expanded from Fragile X syndrome to all Fragile X-associated disorders. Randi is continually on the go as an international spokesperson for Fragile X. Fortunately, she’s only seconds away by phone when we need to call upon her for her guidance, advice, and wisdom.

Reymundo Lozano, MD

Mount Sinai, Icahn School of Medicine
Assistant Professor, Department of Genetics and Genomic Sciences and Department of Pediatrics

Dr. Reymundo Lozano, an assistant professor in the Department of Genetics and Genomic Sciences and Department of Pediatrics at the Icahn School of Medicine at Mount Sinai in New York, is an adult and pediatric clinical geneticist with research training in neurodevelopmental and neurodegenerative disorders. He is the director of the Mt. Sinai Fragile X Spectrum Disorder Clinic, and as a collaborator on clinical trials in Fragile X syndrome, Dr. Lozano is committed to finding new pharmacological treatments.

Dr. Lozano enjoys working with the Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome scientific and medical communities, patients, and families utilizing current and innovative treatment strategies to ameliorate patients’ medical challenges. Dr. Lozano is also a member of the NFXF board of directors and the Clinical Trials Committee.

Nicole Tartaglia, MD

Children’s Hospital Colorado, Colorado School of Medicine
Developmental Pediatrics, Department of Pediatrics

Dr. Nicole Tartaglia attended university and medical school at the University of Colorado. She completed her training in general pediatrics at Children’s Hospital Los Angeles, and fellowship training in developmental-behavioral pediatrics at the University of California Davis MIND Institute, where her research focused on children and adults with developmental disabilities, chromosomal abnormalities, Fragile X syndrome, and autism spectrum disorder. She also obtained her master’s in clinical investigation from the University of Colorado Graduate School.

Since 2007, Dr. Tartaglia has worked as faculty for the Colorado School of Medicine at Children’s Hospital Colorado in the Department of Pediatrics Section of Developmental Pediatrics, where she founded and directs the eXtraordinarY Kids Clinic for children and adolescents with sex chromosome disorders, and is also the director of the Denver Fragile X Clinic. In these clinics, she leads multidisciplinary teams that include medical providers, genetic counseling, psychology, speech-language therapy, occupational therapy, nursing, and social work, and collaborates extensively with community providers, therapists, and schools to provide optimal care for these special populations.  She also evaluates and treats children with general developmental delays, autism spectrum disorder, ADHD, and other neurogenetic disorders.

Dr. Tartaglia has federally funded research projects evaluating natural history and outcome measures in sex chromosome disorders and Fragile X and collaborates with national networks of clinics to develop best practices for treatments of these conditions. She is also very active in clinical trials of targeted treatment medications for neurobehavioral features and developmental disabilities. Dr. Tartaglia is also a member of the NFXF’s Clinical Trials Committee.


Hilary Rosselot

National Fragile X Foundation
Executive Director & Research Facilitation Lead

Hilary Rosselot is the executive director of the National Fragile X Foundation and leads the Research Facilitation programming. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a Clinical Research Coordinator across many types of clinical trials and served as the Clinical Research Manager for the Cincinnati program.